{"schema_version":"secwatch.filing_event.v1","accession":"0001551306-22-000038","form_type":"8-K","ticker":"PGNY","cik":"0001551306","company_name":"Progyny, Inc.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.112499+00:00","generated_at":"2026-06-21T12:43:47.376386+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M","bullets":["Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.","Net income guided to $28.5-29.5M ($0.28-0.29 diluted EPS); adjusted EBITDA $124-125.5M.","Q4 2022 revenue projected at $208.9-213.9M (64-68% growth); net income $1.5-2.5M.","Guidance increase due to resumed shipments of Menopur, a key fertility medication, after industry-wide shortage.","Company now serves >370 clients representing 5.4 million members as it enters 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-22-000038","json":"https://secwatch.observer/filing/0001551306-22-000038.json","markdown":"https://secwatch.observer/filing/0001551306-22-000038.md","text":"https://secwatch.observer/filing/0001551306-22-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/0001551306-22-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/pgny-20221128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:43:47.376386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}